We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
DxGen

Eurofins Technologies

  Silver Eurofins Technologies, part of the Eurofins Scientific group, is a fast-growing, global provider of diagnostic test k... read more Featured Products: More products

Download Mobile App





Eurofins Launches COVID-19 PCR Tests with At-Home Self-Sampling Options in Europe

By LabMedica International staff writers
Posted on 24 Dec 2020
Print article
Image: SARS-CoV-2 PCR test (Photo courtesy of Eurofins Technologies)
Image: SARS-CoV-2 PCR test (Photo courtesy of Eurofins Technologies)
Eurofins Technologies (Budapest, Hungary) has launched EmpowerDX SARS CoV 2 RT PCR test with at home sampling option after it received an Emergency Use Authorization (EUA) by the FDA.

To make patient sampling easier by non-healthcare professionals and especially for testing children, Eurofins validated a sampling method based on gargling with a sterile solution. At-home gargling self-sampling offers the advantage of a simple non-invasive sampling method, allowing patients to be tested without any constraint of medical sampling capacity.
New
Platinum Supplier
SARS-CoV-2/Influenza A & B/RSV Test
BIOSYNEX® AMPLIQUICK® SARS-COV-2 and Respiratory Triplex
New
COVID-19 Anitibody Test
TGS COVID-19 IgG
Visit expo >

The kit is delivered to the patient and collected after self-sampling, with results delivered in less than 24 hours. As this product can significantly expand access to testing, Eurofins will apply for regulatory approval to launch similar tests in the UK, France, Belgium, Netherlands and Sweden, amongst others. These tests will also detect VUI2020-12/01 virus variants recently reported to be spreading quickly in the UK. Eurofins Genomics also has significant sequencing capacity to identify this or other variants of the virus.

Given the limited understanding of the prevalence of this new variant in Europe and the consequent potential pandemic acceleration, Eurofins has decided to donate part of its sequencing capacity to national public health authorities who do not have already approved funding to identify VUI2020-12/01 in their positive samples to evaluate local prevalence of this new strain. This knowledge may be useful in deciding on local isolation and travel restrictions.

A version of this product is derived from a test developed by Eurofins Viracor in March 2020 which was ranked by the FDA as the most sensitive out of more than 115 kits evaluated with the FDA reference panel evaluation.


Print article

Channels

Molecular Diagnostics

view channel
Image: Histopathology of neurofibrillary tangles in the brain of a patient with Alzheimer`s disease (Bielschowski silver stain) (Photo courtesy of Dimitri P. Agamanolis, MD).

Alzheimer's Disease Subtypes Proposed from Brain Gene Expression Profiles

Alzheimer’s disease (AD) is the most common form of dementia in the elderly, estimated to affect more than 5.8 million individuals in the USA and more than 50 million worldwide, with almost half of individuals... Read more

Industry

view channel
Illustration

Thermo Fisher Acquires Point-of-Care Molecular Diagnostics Provider Mesa Biotech

Thermo Fisher Scientific Inc. (Waltham, MA, USA) has entered into a definitive agreement to acquire Mesa Biotech (San Diego, CA, USA), a privately held molecular diagnostic company, for approximately USD... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.